Recent Insights into the Management of Inflammation in Asthma

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: www.ginasthma.org. Accessed August 17, 2021.
   Google Scholar
• Rackemann FM. A working classification of asthma. Am J Med. 1947;3(5):601–606. doi:10.1016/0002-9343(47)90204-0
   PubMed Web of Science ®Google Scholar
• Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet. 1958;272(7059):1245–1247. doi:10.1016/S0140-6736(58)91385-0
   Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–1008. doi:10.1164/ajrccm.160.3.9812110
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:10.1164/rccm.200903-0392OC
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. doi:10.1038/ni.3049
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975–991. doi:10.1016/j.immuni.2019.03.018
   PubMed Web of Science ®Google Scholar
• Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130(4):829–842; quiz 843–824. doi:10.1016/j.jaci.2012.06.034
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779–788. doi:10.1172/JCI5909
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Chipps BE, Holguin F, Woodruff PG. T2-”low” asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452–463. doi:10.1016/j.jaip.2019.11.006
   PubMed Web of Science ®Google Scholar
• Rakowski E, Zhao S, Liu M, et al. Variability of blood eosinophils in patients in a clinic for severe asthma. Clin Exp Allergy. 2019;49(2):163–170. doi:10.1111/cea.13310
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5):1532–1539. doi:10.1164/ajrccm.160.5.9806170
   PubMed Web of Science ®Google Scholar
• Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104(8):1131–1137. doi:10.1016/j.rmed.2010.02.018
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Prefontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–1187. doi:10.1016/j.jaci.2009.02.024
   PubMed Web of Science ®Google Scholar
• Tliba O, Panettieri RA. Paucigranulocytic asthma: uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol. 2019;143(4):1287–1294. doi:10.1016/j.jaci.2018.06.008
   PubMed Web of Science ®Google Scholar
• Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574–584. doi:10.1016/S2213-2600(16)30048-0
   PubMed Web of Science ®Google Scholar
• (GINA) GIFA. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. 2019.
   Google Scholar
• (GINA) GIFA. Global strategy for asthma management and prevention. 2020.
   Google Scholar
• Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK severe asthma registry in the biologic era. Thorax. 2021;76(3):220–227. doi:10.1136/thoraxjnl-2020-215168
   PubMed Web of Science ®Google Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021:In Press. doi:10.1016/j.chest.2021.04.013
   PubMed Web of Science ®Google Scholar
• Azim A, Newell C, Barber C, et al. Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts. Clin Exp Allergy. 2021;51(6):811–820. doi:10.1111/cea.13841
   PubMed Web of Science ®Google Scholar
• Azim A, Freeman A, Lavenu A, et al. New perspectives on difficult asthma; sex and age of asthma-onset based phenotypes. J Allergy Clin Immunol Pract. 2020;8(10):3396–3406 e3394. doi:10.1016/j.jaip.2020.05.053
   PubMed Web of Science ®Google Scholar
• Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–1807. doi:10.1016/j.jaci.2016.08.048
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi:10.1164/rccm.200906-0896OC
   PubMed Web of Science ®Google Scholar
• Fong WCG, Azim A, Knight D, et al. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes. Clin Exp Allergy. 2021;51:1019–1032. doi:10.1111/cea.13882
   PubMed Web of Science ®Google Scholar
• Molina C, Brun J, Coulet M, Betail G, Delage J. Immunopathology of the bronchial mucosa in ‘late onset’ asthma. Clin Allergy. 1977;7(2):137–145. doi:10.1111/j.1365-2222.1977.tb01434.x
   PubMedGoogle Scholar
• Djukanovic R, Wilson JW, Britten KM, et al. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis. 1990;142(4):863–871. doi:10.1164/ajrccm/142.4.863
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Peters SP, Djukanovic R, Calhoun WJ. Investigative use of bronchoscopy in asthma. Am J Respir Crit Care Med. 1998;157(3):692–697. doi:10.1164/ajrccm.157.3.9705020
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi:10.1111/j.1440-1843.2006.00784.x
   PubMed Web of Science ®Google Scholar
• Louis R, Sele J, Henket M, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy. 2002;57(10):907–912. doi:10.1034/j.1398-9995.2002.23608.x
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721. doi:10.1016/S0140-6736(02)11679-5
   PubMed Web of Science ®Google Scholar
• Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax. 2012;67(3):193–198. doi:10.1136/thx.2010.156836
   PubMed Web of Science ®Google Scholar
• Jones TB, Elliott T, Rupani S, et al. Characteristics of eosinophilic severe asthmatics in the Wessex Severe Asthma Cohort (WSAC). Eur Respir J. 2017;50:PA4042.
   Web of Science ®Google Scholar
• Ricciardolo FL. Revisiting the role of exhaled nitric oxide in asthma. Curr Opin Pulm Med. 2014;20(1):53–59. doi:10.1097/MCP.0000000000000006
   PubMed Web of Science ®Google Scholar
• Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy. 2008;38(6):936–946. doi:10.1111/j.1365-2222.2008.02969.x
   PubMed Web of Science ®Google Scholar
• Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med. 2000;162(2):701–706. doi:10.1164/ajrccm.162.2.9908132
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Ten Brinke A, Sterk PJ, et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin Exp Allergy. 2014;44(2):212–221. doi:10.1111/cea.12179
   PubMed Web of Science ®Google Scholar
• Coumou H, Westerhof GA, de Nijs SB, Zwinderman AH, Bel EH. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J. 2018;51(2):1701785. doi:10.1183/13993003.01785-2017
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Hirano T, Oka A, Ito K, Edakuni N. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int. 2016;65(3):266–271. doi:10.1016/j.alit.2015.12.006
   PubMed Web of Science ®Google Scholar
• Vijverberg SJ, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: from bench to bedside. Biologics. 2013;7:199–210.
   PubMedGoogle Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST
   PubMed Web of Science ®Google Scholar
• Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6(1):29–39. doi:10.1016/S2213-2600(17)30424-1
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:10.1016/j.jaci.2020.10.003
   PubMed Web of Science ®Google Scholar
• McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2012;186(11):1102–1108. doi:10.1164/rccm.201204-0587OC
   PubMed Web of Science ®Google Scholar
• Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–1119. doi:10.1136/thoraxjnl-2018-211540
   PubMed Web of Science ®Google Scholar
• Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi:10.1016/S2213-2600(15)00050-8
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl JMed. 2018;378:2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-205634
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51(4):1702536. doi:10.1183/13993003.02536-2017
   PubMed Web of Science ®Google Scholar
• Tan WC, Bourbeau J, Nadeau G, et al. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2020;57:2000838.
   Web of Science ®Google Scholar
• Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. JAA. 2016;9:1–12.
   Google Scholar
• Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi:10.1164/rccm.201903-0599LE
   PubMed Web of Science ®Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858. doi:10.1016/S2213-2600(15)00367-7
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, Leonardi S, Marseglia GL. Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice. Breathe. 2020;16(1):190301. doi:10.1183/20734735.0301-2019
   Web of Science ®Google Scholar
• Pavord ID, Afzalnia S, Menzies-Gow A, Heaney LG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy. 2017;47(2):148–160. doi:10.1111/cea.12881
   PubMed Web of Science ®Google Scholar
• Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104. doi:10.1016/j.jaci.2006.02.046
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 2007;104(40):15858–15863. doi:10.1073/pnas.0707413104
   PubMed Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–654.e610. doi:10.1016/j.jaci.2012.06.025
   PubMed Web of Science ®Google Scholar
• Couillard S, Laugerud A, Jabeen M, et al. A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE). Am J Respir Crit Care Med. 2021;203:A1436.
   Web of Science ®Google Scholar
• Parikh NI, Vasan RS. Assessing the clinical utility of biomarkers in medicine. Biomark Med. 2007;1(3):419–436. doi:10.2217/17520363.1.3.419
   PubMed Web of Science ®Google Scholar
• Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21–37.
   PubMed Web of Science ®Google Scholar
• Specjalski K, Niedoszytko M. MicroRNAs: future biomarkers and targets of therapy in asthma? Curr Opin Pulm Med. 2020;26(3):285–292. doi:10.1097/MCP.0000000000000673
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang S, Fang X, et al. Plasma miR-199a-5p is increased in neutrophilic phenotype asthma patients and negatively correlated with pulmonary function. PLoS One. 2018;13(3):e0193502. doi:10.1371/journal.pone.0193502
   PubMed Web of Science ®Google Scholar
• Tian M, Zhou Y, Jia H, Zhu X, Cui Y. The clinical significance of changes in the expression levels of MicroRNA-1 and inflammatory factors in the peripheral blood of children with acute-stage asthma. Biomed Res Int. 2018;2018:7632487. doi:10.1155/2018/7632487
   PubMed Web of Science ®Google Scholar
• Maes T, Cobos FA, Schleich F, et al. Asthma inflammatory phenotypes show differential microRNA expression in sputum. J Allergy Clin Immunol. 2016;137(5):1433–1446. doi:10.1016/j.jaci.2016.02.018
   PubMed Web of Science ®Google Scholar
• Zhao M, Juanjuan L, Weijia F, et al. Expression levels of microRNA-125b in serum exosomes of patients with asthma of different severity and its diagnostic significance. Curr Drug Metab. 2019;20(10):781–784. doi:10.2174/1389200220666191021100001
   PubMed Web of Science ®Google Scholar
• Rodrigo-Munoz JM, Canas JA, Sastre B, et al. Asthma diagnosis using integrated analysis of eosinophil microRNAs. Allergy. 2019;74(3):507–517. doi:10.1111/all.13570
   PubMed Web of Science ®Google Scholar
• de Vries R, Dagelet YWF, Spoor P, et al. Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. Eur Respir J. 2018;51(1):1701817. doi:10.1183/13993003.01817-2017
   PubMed Web of Science ®Google Scholar
• Schleich FN, Zanella D, Stefanuto PH, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med. 2019;200(4):444–453. doi:10.1164/rccm.201811-2210OC
   PubMed Web of Science ®Google Scholar
• Brinkman P, van de Pol MA, Gerritsen MG, et al. Exhaled breath profiles in the monitoring of loss of control and clinical recovery in asthma. Clin Exp Allergy. 2017;47(9):1159–1169. doi:10.1111/cea.12965
   PubMed Web of Science ®Google Scholar
• Peel AM, Wilkinson M, Sinha A, Loke YK, Fowler SJ, Wilson AM. Volatile organic compounds associated with diagnosis and disease characteristics in asthma - a systematic review. Respir Med. 2020;169:105984. doi:10.1016/j.rmed.2020.105984
   PubMed Web of Science ®Google Scholar
• Holz O, Waschki B, Watz H, et al. Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort. Eur Respir J. 2021;57(2):2002127. doi:10.1183/13993003.02127-2020
   PubMed Web of Science ®Google Scholar
• Kolmert J, Gomez C, Balgoma D, et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study. Am J Respir Crit Care Med. 2021;203(1):37–53. doi:10.1164/rccm.201909-1869OC
   PubMed Web of Science ®Google Scholar
• Hagan JB, Laidlaw TM, Divekar R, et al. Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2017;5(4):990–997 e991. doi:10.1016/j.jaip.2016.11.004
   PubMed Web of Science ®Google Scholar
• Ostling J, van Geest M, Schofield JPR, et al. IL-17-high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol. 2019;144(5):1198–1213. doi:10.1016/j.jaci.2019.03.027
   PubMed Web of Science ®Google Scholar
• Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–883 e871. doi:10.1016/j.jaci.2014.10.026
   PubMed Web of Science ®Google Scholar
• Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J Allergy Clin Immunol Pract. 2021;9:2680–2688.e7. doi:10.1016/j.jaip.2021.02.059
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127(2):382–389. doi:10.1016/j.jaci.2010.11.015
   PubMed Web of Science ®Google Scholar
• Kurukulaaratchy RJ, Zhang H, Raza A, et al. The diversity of young adult wheeze: a cluster analysis in a longitudinal birth cohort. Clin Exp Allergy. 2014;44(5):724–735. doi:10.1111/cea.12306
   PubMed Web of Science ®Google Scholar
• Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• Freitas PD, Xavier RF, McDonald VM, et al. Identification of asthma phenotypes based on extrapulmonary treatable traits. Eur Respir J. 2021;57(1):2000240. doi:10.1183/13993003.00240-2020
   PubMed Web of Science ®Google Scholar
• McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47. doi:10.1111/resp.13389
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Hekking PP, Shaw DE, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy. 2019;74(2):406–411. doi:10.1111/all.13629
   PubMed Web of Science ®Google Scholar
• Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–1390. doi:10.1111/resp.12838
   PubMed Web of Science ®Google Scholar
• McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020;55(3):1901509. doi:10.1183/13993003.01509-2019
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. doi:10.1056/NEJMoa0805435
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879. doi:10.1136/thorax.57.10.875
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–1563 e1555. doi:10.1016/j.jaci.2013.10.011
   PubMed Web of Science ®Google Scholar
• Shaw DE, Berry MA, Hargadon B, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132(6):1871–1875. doi:10.1378/chest.07-1047
   PubMed Web of Science ®Google Scholar
• Boulet LP, Lemiere C, Archambault F, Carrier G, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest. 2006;129(3):661–668. doi:10.1378/chest.129.3.661
   PubMed Web of Science ®Google Scholar
• Green BJ, Wiriyachaiporn S, Grainge C, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One. 2014;9(6):e100645. doi:10.1371/journal.pone.0100645
   PubMed Web of Science ®Google Scholar
• McCreanor J, Cullinan P, Nieuwenhuijsen MJ, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med. 2007;357(23):2348–2358. doi:10.1056/NEJMoa071535
   PubMed Web of Science ®Google Scholar
• Hastie AT, Mauger DT, Denlinger LC, et al. Mixed sputum granulocyte longitudinal impact on lung function in the severe asthma research program. Am J Respir Crit Care Med. 2021;203(7):882–892. doi:10.1164/rccm.202009-3713OC
   PubMed Web of Science ®Google Scholar
• Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028–1036 e1013. doi:10.1016/j.jaci.2010.02.008
   PubMed Web of Science ®Google Scholar
• Ntontsi P, Loukides S, Bakakos P, et al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes. Allergy. 2017;72(11):1761–1767. doi:10.1111/all.13184
   PubMed Web of Science ®Google Scholar
• Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne). 2017;4:158. doi:10.3389/fmed.2017.00158
   PubMed Web of Science ®Google Scholar
• Shin B, Kwon HS, Park SY, Kim TB, Moon HB, Cho YS. The transition of sputum inflammatory cell profiles is variable in stable asthma patients. Asia Pac Allergy. 2017;7(1):19–28. doi:10.5415/apallergy.2017.7.1.19
   PubMedGoogle Scholar
• Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006;27(3):615–626. doi:10.1183/09031936.06.00074705
   PubMed Web of Science ®Google Scholar
• Rick EM, Woolnough K, Pashley CH, Wardlaw AJ. Allergic fungal airway disease. J Investig Allergol Clin Immunol. 2016;26(6):344–354. doi:10.18176/jiaci.0122
   PubMed Web of Science ®Google Scholar
• Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med. 2010;182(11):1362–1368. doi:10.1164/rccm.201001-0087OC
   PubMed Web of Science ®Google Scholar
• Goh KJ, Yii ACA, Lapperre TS, et al. Sensitization to Aspergillus species is associated with frequent exacerbations in severe asthma. J Asthma Allergy. 2017;10:131–140. doi:10.2147/JAA.S130459
   PubMed Web of Science ®Google Scholar
• Medrek SK, Kao CC, Yang DH, Hanania NA, Parulekar AD. Fungal sensitization is associated with increased risk of life-threatening asthma. J Allergy Clin Immunol Pract. 2017;5(4):1025–1031 e1022. doi:10.1016/j.jaip.2016.11.015
   PubMed Web of Science ®Google Scholar
• Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy. 2011;66(5):679–685. doi:10.1111/j.1398-9995.2010.02542.x
   PubMed Web of Science ®Google Scholar
• O’Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med. 2005;5:4. doi:10.1186/1471-2466-5-4
   PubMedGoogle Scholar
• Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol. 1995;95(5):955–961. doi:10.1016/S0091-6749(95)70095-1
   PubMed Web of Science ®Google Scholar
• Woolnough KF, Richardson M, Newby C, et al. The relationship between biomarkers of fungal allergy and lung damage in asthma. Clin Exp Allergy. 2017;47(1):48–56. doi:10.1111/cea.12848
   PubMed Web of Science ®Google Scholar
• Wark PA, Saltos N, Simpson J, Slater S, Hensley MJ, Gibson PG. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. Eur Respir J. 2000;16(6):1095–1101. doi:10.1034/j.1399-3003.2000.16f13.x
   PubMed Web of Science ®Google Scholar
• Denning DW, Pashley C, Hartl D, et al. Fungal allergy in asthma-state of the art and research needs. Clin Transl Allergy. 2014;4:14. doi:10.1186/2045-7022-4-14
   PubMed Web of Science ®Google Scholar
• Li JX, Fan LC, Li MH, Cao WJ, Xu JF. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature. Respir Med. 2017;122:33–42. doi:10.1016/j.rmed.2016.11.019
   PubMed Web of Science ®Google Scholar
• Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev. 2004;2004(3):CD001108. doi:10.1002/14651858.CD001108.pub2
   PubMedGoogle Scholar
• Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur Respir J. 2000;16(3):432–436. doi:10.1034/j.1399-3003.2000.016003432.x
   PubMed Web of Science ®Google Scholar
• Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143(5 Pt 1):1025–1029. doi:10.1164/ajrccm/143.5_Pt_1.1025
   PubMedGoogle Scholar
• White AA, Stevenson DD, Longo DL. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060–1070. doi:10.1056/NEJMra1712125
   PubMed Web of Science ®Google Scholar
• Adelman J, McLean C, Shaigany K, Krouse JH. The role of surgery in management of Samter’s triad: a systematic review. Otolaryngol Head Neck Surg. 2016;155(2):220–237. doi:10.1177/0194599816640723
   PubMed Web of Science ®Google Scholar
• Sommer DD, Rotenberg BW, Sowerby LJ, et al. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016;6(4):385–391. doi:10.1002/alr.21678
   PubMed Web of Science ®Google Scholar
• Waldram J, Walters K, Simon R, Woessner K, Waalen J, White A. Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study. J Allergy Clin Immunol. 2018;141(1):250–256. doi:10.1016/j.jaci.2017.05.006
   PubMed Web of Science ®Google Scholar
• Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha, 11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585–1587 e1584. doi:10.1016/j.jaci.2015.09.034
   PubMed Web of Science ®Google Scholar
• Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy. 2003;58(8):691–706. doi:10.1034/j.1398-9995.2003.00105.x
   PubMed Web of Science ®Google Scholar
• de Groot EP, Nijkamp A, Duiverman EJ, Brand PL. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax. 2012;67(7):582–587. doi:10.1136/thoraxjnl-2011-201168
   PubMed Web of Science ®Google Scholar
• Kurukulaaratchy RJ, Zhang H, Patil V, et al. Identifying the heterogeneity of young adult rhinitis through cluster analysis in the Isle of Wight birth cohort. J Allergy Clin Immunol. 2015;135(1):143–150. doi:10.1016/j.jaci.2014.06.017
   PubMed Web of Science ®Google Scholar
• Scichilone N, Arrigo R, Paterno A, et al. The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma. J Asthma. 2011;48(1):41–47. doi:10.3109/02770903.2010.528821
   PubMed Web of Science ®Google Scholar
• Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017;47(7):856–889.
   PubMed Web of Science ®Google Scholar
• Bilodeau L, Boulay ME, Prince P, Boisvert P, Boulet LP. Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology. 2010;48(4):420–425. doi:10.4193/Rhino09.095
   PubMed Web of Science ®Google Scholar
• Hakansson K, Bachert C, Konge L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported. PLoS One. 2015;10(7):e0127228. doi:10.1371/journal.pone.0127228
   PubMed Web of Science ®Google Scholar
• Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67(1):91–98. doi:10.1111/j.1398-9995.2011.02709.x
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Patou J, van Zele T, Gevaert P. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol. 2008;8(1):34–38. doi:10.1097/ACI.0b013e3282f4178f
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020;58(2):82–111. doi:10.4193/Rhin20.601
   PubMedGoogle Scholar
• Al Badaai Y, Valdes CJ, Samaha M. Outcomes and cost benefits of functional endoscopic sinus surgery in severely asthmatic patients with chronic rhinosinusitis. J Laryngol Otol. 2014;128(6):512–517. doi:10.1017/S0022215114001133
   PubMed Web of Science ®Google Scholar
• Chen FH, Zuo KJ, Guo YB, et al. Long-term results of endoscopic sinus surgery-oriented treatment for chronic rhinosinusitis with asthma. Laryngoscope. 2014;124(1):24–28. doi:10.1002/lary.24196
   PubMed Web of Science ®Google Scholar
• Ragab S, Scadding GK, Lund VJ, Saleh H. Treatment of chronic rhinosinusitis and its effects on asthma. Eur Respir J. 2006;28(1):68–74. doi:10.1183/09031936.06.00043305
   PubMed Web of Science ®Google Scholar
• Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011;127(6):1486–1493 e1482. doi:10.1016/j.jaci.2011.03.036
   PubMed Web of Science ®Google Scholar
• Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755–767. doi:10.1080/17476348.2018.1506331
   PubMed Web of Science ®Google Scholar
• Brumpton BM, Camargo CA, Romundstad PR, Langhammer A, Chen Y, Mai XM. Metabolic syndrome and incidence of asthma in adults: the HUNT study. Eur Respir J. 2013;42(6):1495–1502. doi:10.1183/09031936.00046013
   PubMed Web of Science ®Google Scholar
• Forno E, Han YY, Muzumdar RH, Celedon JC. Insulin resistance, metabolic syndrome, and lung function in US adolescents with and without asthma. J Allergy Clin Immunol. 2015;136(2):304–311 e308. doi:10.1016/j.jaci.2015.01.010
   PubMed Web of Science ®Google Scholar
• Kattan M, Kumar R, Bloomberg GR, et al. Asthma control, adiposity, and adipokines among inner-city adolescents. J Allergy Clin Immunol. 2010;125(3):584–592. doi:10.1016/j.jaci.2010.01.053
   PubMed Web of Science ®Google Scholar
• Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J. 2011;38(3):594–602. doi:10.1183/09031936.00139810
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Tsugawa Y, Chang Y, Camargo CA. Risk of an asthma exacerbation after bariatric surgery in adults. J Allergy Clin Immunol. 2015;136(2):288–294 e288. doi:10.1016/j.jaci.2014.12.1931
   PubMed Web of Science ®Google Scholar
• Nyenhuis SM, Dixon AE, Ma J. Impact of lifestyle interventions targeting healthy diet, physical activity, and weight loss on asthma in adults: what is the evidence? J Allergy Clin Immunol Pract. 2018;6(3):751–763. doi:10.1016/j.jaip.2017.10.026
   PubMed Web of Science ®Google Scholar
• Okoniewski W, Lu KD, Forno E. Weight loss for children and adults with obesity and asthma. A systematic review of randomized controlled trials. Ann Am Thorac Soc. 2019;16(5):613–625. doi:10.1513/AnnalsATS.201810-651SR
   PubMed Web of Science ®Google Scholar
• van Huisstede A, Rudolphus A, Castro Cabezas M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax. 2015;70(7):659–667. doi:10.1136/thoraxjnl-2014-206712
   PubMed Web of Science ®Google Scholar
• Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230. doi:10.1136/thorax.57.3.226
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8):783–790. doi:10.1164/rccm.200511-1746OC
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174(2):127–133. doi:10.1164/rccm.200510-1589OC
   PubMed Web of Science ®Google Scholar
• Perret JL, Bonevski B, McDonald CF, Abramson MJ. Smoking cessation strategies for patients with asthma: improving patient outcomes. J Asthma Allergy. 2016;9:117–128. doi:10.2147/JAA.S85615
   PubMedGoogle Scholar
• Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817–822. doi:10.1164/rccm.200902-0166OC
   PubMed Web of Science ®Google Scholar
• Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751–753. doi:10.1136/thoraxjnl-2011-201096
   PubMed Web of Science ®Google Scholar
• Alahmadi F, Peel A, Keevil B, Niven R, Fowler SJ. Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: a literature review. Clin Exp Allergy. 2021;51(1):49–62. doi:10.1111/cea.13787
   PubMed Web of Science ®Google Scholar
• Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111. doi:10.1080/02770903.2019.1663429
   PubMed Web of Science ®Google Scholar
• Heaney LG, Busby J, Bradding P, et al. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454–464. doi:10.1164/rccm.201806-1182OC
   PubMed Web of Science ®Google Scholar
• Moore A, Preece A, Sharma R, et al. A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. Eur Respir J. 2021;57(6):2003103. doi:10.1183/13993003.03103-2020
   PubMed Web of Science ®Google Scholar
• Mosnaim G, Safioti G, Brown R, et al. Digital health technology in asthma: a comprehensive scoping review. J Allergy Clin Immunol Pract. 2021;9:2377–2398. doi:10.1016/j.jaip.2021.02.028
   PubMed Web of Science ®Google Scholar
• Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–220. doi:10.1016/j.anai.2013.06.008
   PubMed Web of Science ®Google Scholar
• Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. Allergy Asthma Clin Immunol. 2020;16:75. doi:10.1186/s13223-020-00472-8
   PubMed Web of Science ®Google Scholar
• Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. doi:10.1111/j.1398-9995.2007.01394.x
   PubMed Web of Science ®Google Scholar
• Miller MK, Lee JH, Miller DP, Wenzel SE, Group TS. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101(3):481–489. doi:10.1016/j.rmed.2006.07.005
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–336. doi:10.1056/NEJM200008033430504
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–884. doi:10.1136/thorax.57.10.880
   PubMed Web of Science ®Google Scholar
• Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006;61(8):663. doi:10.1136/thx.2005.055699
   PubMed Web of Science ®Google Scholar
• Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455–468. doi:10.4187/respcare.03200
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, FitzGerald JM. As-needed budesonide-formoterol in mild asthma. N Engl J Med. 2018;379(9):898.
   PubMed Web of Science ®Google Scholar
• Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014;133(1):39–41. doi:10.1016/j.jaci.2013.10.053
   PubMed Web of Science ®Google Scholar
• Price D, Fletcher M, van der Molen T. Asthma control and management in 8000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi:10.1038/npjpcrm.2014.9
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:10.1056/NEJMoa1715274
   PubMed Web of Science ®Google Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide–formoterol as needed for mild asthma. N Engl JMed. 2019;380(21):2020–2030. doi:10.1056/NEJMoa1901963
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496. doi:10.1001/jama.2018.2769
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999;160(2):594–599. doi:10.1164/ajrccm.160.2.9811100
   PubMed Web of Science ®Google Scholar
• Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537):744–753. doi:10.1016/S0140-6736(06)69284-2
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61(5):725–736. doi:10.1111/j.1742-1241.2007.01338.x
   PubMed Web of Science ®Google Scholar
• Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101(12):2437–2446. doi:10.1016/j.rmed.2007.07.014
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Krishnan JA, King TS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl JMed. 2019;380(21):2009–2019. doi:10.1056/NEJMoa1814917
   PubMed Web of Science ®Google Scholar
• Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allerg Clin Immunol. 2009;124(6):S88–S93. doi:10.1016/j.jaci.2009.09.050
   PubMed Web of Science ®Google Scholar
• Bacsi A, Choudhury BK, Dharajiya N, Sur S, Boldogh I. Subpollen particles: carriers of allergenic proteins and oxidases. J Allergy Clin Immunol. 2006;118(4):844–850. doi:10.1016/j.jaci.2006.07.006
   PubMed Web of Science ®Google Scholar
• Taylor PE, Flagan RC, Valenta R, Glovsky MM. Release of allergens as respirable aerosols: a link between grass pollen and asthma. J Allergy Clin Immunol. 2002;109(1):51–56. doi:10.1067/mai.2002.120759
   PubMed Web of Science ®Google Scholar
• Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med. 1996;154(3):771–782. doi:10.1164/ajrccm.154.3.8810618
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pedersen S, Usmani OS, et al. Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151(6):1345–1355. doi:10.1016/j.chest.2016.07.035
   PubMed Web of Science ®Google Scholar
• Theron AJ, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:608930. doi:10.1155/2014/608930
   PubMed Web of Science ®Google Scholar
• Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111(1):S18–S34. doi:10.1067/mai.2003.25
   PubMedGoogle Scholar
• Negri J, Early SB, Steinke JW, Borish L. Corticosteroids as inhibitors of cysteinyl leukotriene metabolic and signaling pathways. J Allergy Clin Immunol. 2008;121(5):1232–1237. doi:10.1016/j.jaci.2008.02.007
   PubMed Web of Science ®Google Scholar
• Gyllfors P, Dahlen SE, Kumlin M, Larsson K, Dahlen B. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J Allergy Clin Immunol. 2006;118(1):78–83. doi:10.1016/j.jaci.2006.03.040
   PubMed Web of Science ®Google Scholar
• Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med. 2015;163(10):756–767. doi:10.7326/M15-1059
   PubMed Web of Science ®Google Scholar
• Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287. doi:10.2500/aap.2014.35.3745
   PubMed Web of Science ®Google Scholar
• Marcello C, Carlo L. Asthma phenotypes: the intriguing selective intervention with Montelukast. Asthma Res Pract. 2016;2:11. doi:10.1186/s40733-016-0026-6
   PubMedGoogle Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi:10.1016/S0140-6736(17)31281-3
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329. doi:10.1136/thoraxjnl-2012-202698
   PubMed Web of Science ®Google Scholar
• Shukla SD, Taylor SL, Gibson PG, et al. Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. Thorax. 2021;76:733–736. doi:10.1136/thoraxjnl-2020-216331
   PubMed Web of Science ®Google Scholar
• Niessen NM, Gibson PG, Baines KJ, et al. Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. Allergy. 2021;76:2090–2101. doi:10.1111/all.14768
   PubMed Web of Science ®Google Scholar
• Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, Khakzad MR, Hashemi Attar A, Naghibi S. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: a double-blind placebo-controlled randomized clinical trial. Respir Med. 2021;185:106494. doi:10.1016/j.rmed.2021.106494
   PubMed Web of Science ®Google Scholar
• Taylor SL, Ivey KL, Gibson PG, Simpson JL, Rogers GB. Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma. Eur Respir J. 2020;56(4):2000194. doi:10.1183/13993003.00194-2020
   PubMed Web of Science ®Google Scholar
• Virchow JC. Allergen immunotherapy (AIT) in asthma. Semin Immunol. 2019;46:101334. doi:10.1016/j.smim.2019.101334
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725. doi:10.1001/jama.2016.3964
   PubMed Web of Science ®Google Scholar
• Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019;74(5):855–873. doi:10.1111/all.13749
   PubMed Web of Science ®Google Scholar
• Anonymous. Xolair. European Medicines Agency; 2018.
   Google Scholar
• Anonymous. Nucala. European Medicines Agency; 2018.
   Google Scholar
• Anonymous. Cinqaero. European Medicines Agency; 2018.
   Google Scholar
• Anonymous. Fasenra. European Medicines Agency; 2018.
   Google Scholar
• Anonymous. Dupixent. European Medicines Agency; 2018.
   Google Scholar
• Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018;52(6):1801444. doi:10.1183/13993003.01444-2018
   PubMed Web of Science ®Google Scholar
• Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–233. doi:10.1136/thx.2006.066837
   PubMed Web of Science ®Google Scholar
• Shamji MH, Valenta R, Jardetzky T, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy. 2021;Epub. doi:10.1111/all.14908
   Google Scholar
• Arroyave WD, Rabito FA, Carlson JC. The relationship between a specific IgE level and asthma outcomes: results from the 2005–2006 national health and nutrition examination survey. J Allergy Clin Immunol Pract. 2013;1(5):501–508.
   PubMed Web of Science ®Google Scholar
• Naqvi M, Choudhry S, Tsai H-J, et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allerg Clin Immunol. 2007;120(1):137–143. doi:10.1016/j.jaci.2007.02.045
   PubMed Web of Science ®Google Scholar
• Guntern P, Eggel A. Past, present, and future of anti-IgE biologics. Allergy. 2020;75(10):2491–2502. doi:10.1111/all.14308
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allerg Clin Immunol. 2017;140(1):162–169.e162. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559. doi:10.1002/14651858.CD003559.pub4
   Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 20219(7):2702–2714. doi:10.1016/j.jaip.2021.01.011
   Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e1362. doi:10.1016/j.jaip.2017.02.002
   PubMed Web of Science ®Google Scholar
• Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allerg Asthma Immunol. 2003;91(2):182–188. doi:10.1016/S1081-1206(10)62175-8
   PubMed Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60. doi:10.1016/j.rmed.2017.07.013
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allerg Clin Immunol. 2014;134(3):560–567.e564. doi:10.1016/j.jaci.2014.02.007
   PubMed Web of Science ®Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allerg Clin Immunol. 2015;135(2):407–412. doi:10.1016/j.jaci.2014.08.025
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492. doi:10.1016/j.rmed.2007.01.011
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–1787. doi:10.1111/j.1398-9995.2009.02119.x
   PubMed Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:10.1111/all.13302
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164.e151.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, Gros VL, Just J, Molimard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523. doi:10.1183/13993003.02523-2017
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71(10):1472–1479. doi:10.1111/all.12922
   PubMed Web of Science ®Google Scholar
• Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allerg Asthma Immunol. 2016;116(1):37–42. doi:10.1016/j.anai.2015.10.027
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Menzella F, Caminati M, et al. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation. Allergy. 2019;74(12):2539–2541. doi:10.1111/all.13937
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Pelaia C, D’Amato M, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:1–13. doi:10.1177/1753466620929231
   Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti‐IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):CD010834. doi:10.1002/14651858.CD010834.pub3
   PubMed Web of Science ®Google Scholar
• Park SW, Kim DJ, Chang HS, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. IAA. 2003;131(4):283–290.
   Google Scholar
• Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol. 2004;25(9):477–482. doi:10.1016/j.it.2004.07.006
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl JMed. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl JMed. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Caminati M, Menzella F, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019;58(May):101836. doi:10.1016/j.pupt.2019.101836
   PubMedGoogle Scholar
• Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019
   PubMed Web of Science ®Google Scholar
• Ibrahim H, O’Sullivan R, Casey D, et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respir Res. 2019;20(1):289. doi:10.1186/s12931-019-1251-3
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, D’ Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, D’ Ancona G, et al. Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma. Allergy. 2021;76(6):1890–1893. doi:10.1111/all.14693
   Google Scholar
• Menzella F, Bonavia M, Bonini M, et al. Real-world experience with benralizumab in patients with severe eosinophilic asthma: a case series. JAA. 2021;14:149–161. doi:10.2147/JAA.S295676
   Google Scholar
• Padilla-Galo A, Levy-Abitbol R, Olveira C, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184. doi:10.1186/s12890-020-01220-9
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Vatrella A, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830. doi:10.1016/j.pupt.2019.101830
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allerg. 2020;50(7):780–788. doi:10.1111/cea.13613
   PubMed Web of Science ®Google Scholar
• Schleich F, Graff S, Nekoee H, et al. Real-world experience with mepolizumab: does it deliver what it has promised? Clin Exp Allerg. 2020;50(6):687–695. doi:10.1111/cea.13601
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl JMed. 2017;376(20):1921–1932. doi:10.1056/NEJMoa1702079
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Bakakos P, Loukides S. New paradigm in asthma management: switching between biologics! Allergy. 2020;75(4):743–745. doi:10.1111/all.14038
   PubMed Web of Science ®Google Scholar
• Pérez de Llano LA, Cosío BG, Domingo C, et al. Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: a multicenter, open-label pilot study. J Allergy Clin Immunol. 2019;7(7):2277–2283.e2272.
   Web of Science ®Google Scholar
• Burke H, Davis J, Evans S, Flower L, Tan A, Kurukulaaratchy RJ. A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. ERJ Open Res. 2016;2(3):00039–2016. doi:10.1183/23120541.00039-2016
   PubMedGoogle Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2017;197(1):38–46. doi:10.1164/rccm.201707-1323OC
   Web of Science ®Google Scholar
• Manetz S, Maric I, Brown T, et al. Successful pregnancy in the setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract. 2021;9(3):1405–1407.e1403.
   PubMed Web of Science ®Google Scholar
• Saco T, Tabatabaian F. Breathing for two: a case of severe eosinophilic asthma during pregnancy treated with benralizumab. Ann Allerg Asthma Immunol. 2018;121(5):S92. doi:10.1016/j.anai.2018.09.300
   Web of Science ®Google Scholar
• Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi:10.1016/j.rmed.2019.105806
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allerg Clin Immunol. 2019;143(1):190–200.e120. doi:10.1016/j.jaci.2018.08.031
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2020;158:491–500.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Massolo A, Bonavia M, et al. The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy. 2020;75(6):1460–1463. doi:10.1111/all.14135
   PubMed Web of Science ®Google Scholar
• Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl JMed. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526.
   PubMed Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allerg. 2020;50(7):789–798. doi:10.1111/cea.13614
   PubMed Web of Science ®Google Scholar
• Campisi R, Crimi C, Nolasco S, et al. Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program. JAA. 2021;14:575–583. doi:10.2147/JAA.S312123
   Google Scholar
• Nowsheen S, Darveaux JI. Real-world efficacy and safety of dupilumab use in the treatment of asthma. Ann Allerg Asthma Immunol. 2021;127:147–149. doi:10.1016/j.anai.2021.04.011
   PubMed Web of Science ®Google Scholar
• Renner A, Marth K, Patocka K, Idzko M, Pohl W. Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflam Dis. 2021;9(3):624–627. doi:10.1002/iid3.434
   PubMed Web of Science ®Google Scholar
• Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol. 2021;9(3):1177–1185.e1174.
   Google Scholar
• Bosma AL, Gerbens LA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. Clin Exp Dermatol. 202146(6):1089–1092. doi:10.1111/ced.14725
   Web of Science ®Google Scholar
• Kage P, Simon JC, Treudler R. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. J Eur Acad Dermatol Venereol. 2020;34(6):e256–e257. doi:10.1111/jdv.16235
   PubMed Web of Science ®Google Scholar
• Mian M, Dunlap R, Simpson E. Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: a case report. JAAD Case Rep. 2020;6(10):1051–1052. doi:10.1016/j.jdcr.2020.08.001
   PubMedGoogle Scholar
• Regeneron P. Registry of Asthma Patients Initiating DUPIXENT® (RAPID). 2021. 05 June, 2021. NCT04287621.
   Google Scholar
• Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2021;9(3):1186–1193.e1181.
   Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;Epub. doi:10.1016/S2213-2600(21)00097-7
   Google Scholar
• Takabayashi T, Asaka D, Okamoto Y, et al. A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis. Am J Rhinol Allerg. 2021;Epub. doi:10.1177/19458924211009429
   Web of Science ®Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allerg. 2021;51(6):836–844. doi:10.1111/cea.13852
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–1604. doi:10.1053/j.gastro.2011.07.044
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl JMed. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020;395(10221):371–383. doi:10.1016/S0140-6736(19)33005-3
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155.
   PubMedGoogle Scholar
• Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. doi:10.1183/13993003.00260-2020
   PubMed Web of Science ®Google Scholar
• Brightling C, Kulkarni S, Lambrecht BN, Sandham D, Weiss M, Altman P. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021;68:102030. doi:10.1016/j.pupt.2021.102030
   PubMed Web of Science ®Google Scholar
• Prussin C, Panettieri RA, Bozik ME, Archibald DG, Mather JL, Siddiqui S. Oral dexpramipexole efficacy in lowering blood eosinophils in patients with moderate to severe uncontrolled eosinophilic asthma: study design and baseline data from the AS201 phase 2 trial. Am J Respir Crit Care Med. 2021;203:A1359.
   Web of Science ®Google Scholar